FDA Gives uniQure’s Huntington’s Therapy Priority Review
The FDA accepted uniQure’s application for review and set a May 1, 2027 target date for action on the gene therapy.
Makkler Newsroom · Nov 2, 03:27 PM · 1 min read
Market open· · USD · Data may be delayed
Avg. target $59.33 (+157.9%)
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO